Proteon Therapeutics Announces First Quarter 2018 Financial Results
09 mai 2018 08h10 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
08 mai 2018 07h00 HE
|
Proteon Therapeutics, Inc.
Partners extend existing contract for manufacture of vonapanitase to 2029 as ongoing Phase 3 trial nears completionLonza Pharma & Biotech successfully scaled up a lab process at their Microbial...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
14 mars 2018 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
06 mars 2018 16h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
05 mars 2018 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th
08 nov. 2017 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2017 Financial Results
07 nov. 2017 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017
05 sept. 2017 07h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2017 Financial Results
07 août 2017 17h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
02 août 2017 19h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...